We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Nucleic Acid Purification System Suitable for Clinical Labs

By LabMedica International staff writers
Posted on 15 Aug 2012
An in vitro diagnostic (IVD) system purifies nucleic acids from up to 96 clinical samples in less than 60 minutes.

Called MagNA Pure 96, the CE certified system was launched by Roche (Penzberg, Germany) for automated sample preparation. The system was designed to be suitable for use in clinical laboratories for diagnostic purposes. The IVD version of MagNA Pure 96 has already been introduced in the US.

The MagNA Pure 96 System provides ready-to-use reagents and uses a minimal number of consumables. It can purify nucleic acids from a wide spectrum of human samples. The system provides laboratory information management system (LIMS) connectivity for safe and convenient data transfer. This ensures data integrity and avoids redundant data handling

The MagNA Pure 96 System purifies DNA, RNA, and viral nucleic acids from a wide variety of starting materials using the magnetic glass particle technology developed by Roche. Preprogrammed software protocols are tailored to sample requirements and yield high-purity nucleic acids that are ideal for a broad range of downstream applications.

Hands-on time is reduced by using bar-coded prefilled reagent trays with ready-to-use reagents, disposables, intuitive software, and optimized preprogrammed purification protocols.

Related Links:

Roche


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Chromogenic Culture System
InTray™ COLOREX™ ECC
Thyroid Test
Anti-Thyroid EIA Test

Channels

Clinical Chemistry

view channel
Image: DNlite measures urinary post-translationally modified Fetuin-A (uPTM-FetA), a biomarker linked to kidney stress, inflammation, metabolic dysfunction, and progressive renal injury (Photo courtesy of Bio Preventive Medicine Corp)

Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures

Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read more
ADLM